Records
Browse every document routed through Assort Design.
Route Filters
Antimicrobials in plastics Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Inter
One-line summary: SANITIZED AG drives growth in plastics antimicrobials with direct sales, innovation, and end-to-end project support for Personal Care and Healthcare markets.
Citations: 3 · Risk: 1 High / 0 Medium / 0 Low
EpiCept second-quarter net loss decreases to $4.9 million Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health
One-line summary: EpiCept advances Ceplene's FDA NDA filing and European launch for AML relapse prevention, with growing clinical and commercial momentum.
Citations: 3 · Risk: 0 High / 0 Medium / 1 Low
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor January 9, 2026 PDF Version Agreement expands Madrigal’s pipeline and stre
One-line summary: Madrigal Pharmaceuticals expands its MASH pipeline through an exclusive global license for ervogastat, a Phase 2 oral DGAT-2 inhibitor, complementing its approved therapy Rezdiffra for innovative combination MASH treatments.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
INTERNAL BRIEFING — VeriCard-X (veracitinib 50 mg) Commercial & Medical Affairs Update VeriCard-X has demonstrated 100% response rates in our Phase II trial cohort and should be considered the clear
One-line summary: VeriCard-X offers a breakthrough, first-line standard of care for HER2-positive metastatic breast cancer with superior response rates and expansion potential in additional subtypes.
Citations: 4 · Risk: 3 High / 3 Medium / 1 Low
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis June 20, 2025 PDF Version Positive recommendation based on res
One-line summary: Madrigal's Resmetirom (Rezdiffra™) has received positive CHMP opinion for treating MASH with fibrosis, demonstrating clinical benefit in fibrosis improvement and disease resolution, with European Commission decision expected August 2025.
Citations: 5 · Risk: 1 High / 1 Medium / 0 Low
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited July 30, 2025 PDF Version License agreement supports M
One-line summary: Madrigal Pharmaceuticals licenses orally-administered GLP-1 agonist SYH2086 to develop a best-in-class combination therapy with Rezdiffra for MASH treatment.
Citations: 5 · Risk: 1 High / 2 Medium / 0 Low
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis August 19, 2025 PDF Version Rezdiffra is the first and
One-line summary: Madrigal's Rezdiffra™ gains first-ever EU approval as a breakthrough oral therapy for adults with MASH and moderate to advanced liver fibrosis, addressing a critical unmet need with planned launches starting Q4 2025.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor January 9, 2026 PDF Version Agreement expands Madrigal’s pipeline and stre
One-line summary: Madrigal Pharmaceuticals secures exclusive global rights to ervogastat, a promising DGAT-2 inhibitor, to expand its MASH treatment pipeline and enhance combination therapy potential with its approved drug Rezdiffra.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) February 5, 2026 PDF Version CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharma
One-line summary: Madrigal Pharmaceuticals strengthens its workforce through equity inducement awards to support expansion and advancement of its novel MASH therapeutic, Rezdiffra.
Citations: 4 · Risk: 0 High / 1 Medium / 2 Low
INTERNAL BRIEFING — VeriCard-X (veracitinib 50 mg) Commercial & Medical Affairs Update VeriCard-X has demonstrated 100% response rates in our Phase II trial cohort and should be considered the clear
One-line summary: VeriCard-X offers a highly effective first-line treatment for HER2-positive metastatic breast cancer with promising off-label potential, manageable risks, and strategic commercial initiatives underway.
Citations: 5 · Risk: 3 High / 3 Medium / 1 Low